Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and Hyperuricemia

rosiglitazone has been researched along with Hyperuricemia in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Chen, H; Deng, J; Shao, X; Wang, X; Xia, Y; Xiong, C; Zhou, Q; Zou, H1
Gu, J; Li, C; Li, Y; Meng, D; Miao, Z; Wang, B; Wang, CY; Wang, J; Wang, L; Xing, X; Yan, S; Yuan, Y; Zhang, S1

Other Studies

2 other study(ies) available for rosiglitazone and Hyperuricemia

ArticleYear
Treatment with a PPAR-γ Agonist Protects Against Hyperuricemic Nephropathy in a Rat Model.
    Drug design, development and therapy, 2020, Volume: 14

    Topics: Administration, Oral; Animals; Disease Models, Animal; Hyperuricemia; Kidney Diseases; Male; Neuroprotective Agents; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone

2020
Insulin resistance acts as an independent risk factor exacerbating high-purine diet induced renal injury and knee joint gouty lesions.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2009, Volume: 58, Issue:10

    Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gout; Homeostasis; Hyperuricemia; Hypoglycemic Agents; Insulin Resistance; Knee Joint; Male; Obesity; Organic Anion Transport Protein 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Purines; Rats; Rats, Inbred OLETF; Risk Factors; Rosiglitazone; Thiazolidinediones; Uric Acid

2009